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ABSTRACT 
Objective: To determine tamoxifen (TAM) and its metabolites, endoxifen (END) and 4-hydroxytamoxifen (4-HT) in patients' DBS simultaneously for 
monitoring studies purposes. 
Methods: The UPLC-MS/MS method was developed and validated with clomiphene as the internal standard. Optimization was done by evaluating 
several parameters that affect the efficiency of DBS preparation and analysis of TAM and its metabolites. 
Results: Sample preparation was performed by protein precipitation using methanol. The separation was performed on UPLC Class BEH C18 using 
formic acid 0.1%-formic acid 0.1% in acetonitrile (35:65) as the mobile phase in isocratic mode at 0.25 ml/minute. The mass detection was 
performed on Waters Xevo TQD using ESI+for TAM, END, 4-HT, and clomiphene as internal standard with m/z value: 372.2>72.27; 374.29>58.2; 
388.29>72.19; dan 406.28>100.17 respectively. This method was linear within the range of 5-200 ng/ml for TAM; 1-40 ng/ml for END; and 0.5-20 
ng/ml for 4-HT with r value of ≥0.9983; ≥0.9964; and ≥0.9981. %diff and %CV of the assay were within 15% and within 20% for LLOQ. The method 
was applied to 29 breast cancer patients, where the results lied between 30.29 and 188.63 ng/ml for tamoxifen, 1.45 and 28.77 ng/ml for endoxifen, 
0.21 and 11.28 ng/ml for 4-hydroxytamoxifen. 
Conclusion: This method has successfully fulfilled validation requirement referring to 2011 EMA and 2013 FDA guidelines. The method was 
successfully applied to determine TAM, END, and 4-HT in DBS of breast cancer ER+patients. TAM and its metabolites level in patients were showed 
high variability with END concentration of 2 patients below the clinical threshold. 
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Breast cancer is one of the cancer types with a high percentage of 
mortality in Indonesia [1]. Most of the cases are caused by estrogen 
receptor (ER)-positive cancer, so anticancer from selective estrogen 
receptor modulators (SERMs) are usually used as the first line of the 
adjuvant therapy [2]. Tamoxifen (TAM) is an anticancer of SERMs and it 
is a prodrug that will be metabolized by CYP2D6 into active metabolites 
that have higher affinity to ER than TAM itself [3-5]. TAM is metabolized 
by CYP2D6 enzyme into endoxifen (END) and 4-hydroxytamoxifen (4-
HT), both of which are metabolites with antiestrogenic activity 30 to 
100fold more potent than TAM itself [5]. Cytochrome 2D6 (CYP2D6) 
enzyme is polymorphic, so it might result in different metabolic activities 
for each patient [3-5]. TAM analysis have been done mostly using plasma 
samples, but plasma sampling of breast cancer patients by venipuncture 
is considered invasive and painful to patient [3]. Therefore, it is 
necessary to develop a method for analyzing TAM using sampling that 
considers patient comfort, namely dried blood spot (DBS), in which this 
method is more simple, requires less blood volume, and the analyte is 
more stable [5-7]. However, the levels of analytes in DBS are lower, so a 
more sensitive and selective method of analysis is needed for TAM, END, 
and 4-HT [8]. 
The previous study showed that the efficacy of TAM therapy 
depended on END threshold concentration. Patient who has END 
concentration above 5.9 ng/ml has less recurrence compared to 
patients with END level below the threshold concentration [4]. This 
concentration is extrapolated to DBS, resulted in threshold 
concentration of 3.3 ng/ml in DBS [3]. 
In the present study, the monitoring of TAM, END, and 4-HT through 
quantification in DBS breast cancer patients was developed and 
applied to determine the levels of TAM metabolites in the blood of 
breast cancer patients in Indonesia. This method can be used to 
evaluate the effectiveness of TAM therapy in breast cancer patients 
and can be considered by doctors for follow-up therapy. 
MATERIALS AND METHODS 
Reference standard samples and materials 
TAM was purchased from Sigma-Aldrich (Singapore). N-desmethyl-4-HT 
(ENDE/Z mixture) and 4-HT were purchased from Santa Cruz 
Biotechnology (USA). Clomiphene was purchased from Fabrica Italiana 
Sintetici (Italy). Formic acid, acetonitrile HPLC grade, and methanol for 
analysis were obtained from Merck (Darmstadt, Germany). Perkin Elmer 
226 paper was obtained from Perkin Elmer (USA). 
Preparation of solutions and standards 
TAM, END, and 4-HT stock solutions were prepared in methanol to 
obtain a concentration of 1,000 ng/ml [5]. The stock solution was 
diluted to obtain intermediate solutions at 100 ng/ml. Working 
solutions were prepared by dilution of the intermediate solution 
with methanol. Calibration samples were prepared in whole blood 
diluting working solutions at 1:20 with whole blood free from the 
analytes. Clomiphene stock solution was prepared in methanol at 
1.000 ng/ml concentration. Intermediate clomiphene solutions were 
prepared by dilution of the stock with methanol to obtain a 
concentration of 100 ng/ml. 
Sample preparation 
DBS samples were prepared from freshly drawn whole blood which 
spotted on the DBS paper and dried for 2 h. The method was 
referred to [5] with some modification. The blood spots were cut 
through the spot’s diameter. For the extraction of the analytes from 
the DBS, a 100 μl methanol containing 0.1% clomiphene and 1.000 
μl methanol as an extraction solvent were added to the DBS. Then 
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the tube was vortexed for 1 minute and sonicated for 25 min. 850 μl 
of the sample mixture was dried under a gentle stream of nitrogen 
(55 °C) for 15 minute and the dried extract was dissolved in 100 μl 
0.1% formic acid–0.1% formic acid in acetonitrile (35, 65). The 
sample mixture was centrifuged for 10 min at 3,000 rpm, then 60 μl 
of the supernatant was transferred to an auto sampler vial and 10 μl 
was injected onto the LC-MS/MS system. 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) 
An LC-MS/MS method was previously used for quantification of TAM 
and END in DBS and also 4-HT in plasma [3]. Positive electrospray 
ionization was applied and the transition from precursor into 
product was set at m/z 372.2>72.22 for TAM; 374.29>58.2 for END; 
388.29>72.19 for4-HT; and 406.28>100.17 for clomiphene.  
Validation assay 
Validation assay was performed based on Food and Drug 
Administration (2013) and European Medicines Agency (2011) 
guidelines for validation of bioanalysis [9, 10]. 
Linearity 
Aliquots of 950 μl blank blood were spiked with 50 μl stock 
solutions to obtain eight calibration levels of samples containing 
TAM (5, 10, 25, 50, 75, 100, 150 and 200 ng/ml), END (1, 2, 5, 10, 15, 
20, 30 and 40 ng/ml), and 4-HT (0,5; 1; 2; 5; 7,5; 10; 15 and 20 
ng/ml). Blank, zero, and calibration samples were applied to Perkin 
Elmer 226 paper (3 x 20 μl), dried at room temperature for 2 h and 
analyzed within 24 h. Replicates at each concentration were 
analyzed as described above. Calibration curves were calculated 
relating the area ratios from TAM, END, and 4-HT peaks to the 
clomiphene peak and with the nominal concentrations of the 
calibration samples.  
Lower limit of quantification (LLOQ) 
An independent DBS quality control sample at the lowest point of 
the calibration curve at concentrations of 5.0; 1.0; and 0.5 ng/ml for 
TAM, END, and 4-HT, respectively was included in the accuracy and 
precision experiments. This assay was performed with five 
replicates. The acceptance criteria established for the LLOQ is 
maximum 20% for the % coefficient variation (CV) value. 
Accuracy and precision 
Aliquots of blank blood were spiked with standard solutions to 
obtain 4 types of concentration: LLOQ, Quality control sampel in low, 
medium, high concentration (QCL, QCM, and QCH) containing TAM, 
END, and 4-HT. Samples were extracted with the extraction method 
as described above. This assay was divided into 2 types: within run 
and between run. Both assays were performed with five replicates. 
The acceptance criteria established for the accuracy and precision is 
maximum 20% for the %CV value of LLOQ concentration and 15% 
for the %CV value of QCL, QCM, and QCH concentrations. 
Recovery 
Aliquots of blank blood were spiked with standard solutions into 
obtain QCL, QCM, and QCH concentrations, then samples were 
extracted and injected to the LC-MS/MS system. Standards 
containing TAM, END, and 4-HT on QCL, QCM, and QCH 
concentrations were also injected to the LC-MS/MS system. Both 
assays were performed with three replicates for each concentration. 
The acceptance criteria is established for maximum 15% for the CV 
value. 
Matrix effect 
Standard solutions of TAM, END, and 4-HT were diluted in the 
solvent to obtain QCL and QCH concentrations, then injected into 
the LC-MS/MS system. Furthermore, whole blood from six 
different sources was extracted with the extraction method as 
described above, then the analytes were inserted to the samples 
after the extraction process to obtain QCL and QCH concentrations. 
The assay was performed with two replicates for each 
concentration. Matrix effect is showed by calculating the matrix 
factor. The acceptance criteria established for the matrix effect is 
maximum 15% for the % CV value in the calculation of 
standardized normalized matrix factor. 
Application of the method 
A total of 29 breast cancer patients who were taking adjuvant 
hormonal treatment with TAM (20 mg/day) were enrolled in the 
study. They were given a full explanation of the procedures during 
sampling and signed the informed consent prior to participating in 
this study. The study inclusion criteria were patient that has been 
diagnosed with breast cancer (ER+) and confirmed by 
histopathology report, had received TAM in their therapy regimen 
(20 mg/day) for at least 2 mo and aged 25-55 y old during the blood 
collection. The exclusion criteria were the patient who declared they 
were unwilling to participate in the study by not signing the 
informed consent sheet. 
Finger prick blood samples were collected from 29 breast cancer 
patients of Dharmais Cancer Hospital, Jakarta, Indonesia. Around 
200 μl blood samples were collected from the fingertips. Blood was 
drawn by finger prick technique using lancet and the first drop of 
blood from fingertip was thrown away by rubbing it with alcohol 
swab. The blood drops were collected in a 0.5 ml K3-EDTA micro 
tube. After that, 20 μl blood was immediately transferred to DBS 
paper using a calibrated micropipette and the paper was allowed to 
dry for 2 h at room temperature. After the drying process, the DBS 
paper was stored in plastic seal bag containing desiccant until the 
time of analysis. 
This research has passed the ethical review from the Health 
Research Ethics Committee of the Faculty of Medicine, Universitas 
Indonesia with number 0076/UN2. F1/ETIK/2018 and notification 
of approval from the Health Research Ethics Committee of Dharmais 
Cancer Hospital with number 038/KEPK/III/2018. 
RESULTS AND DISCUSSION 
Chromatography system and preparation of samples 
The LC-MS/MS system analyzed TAM, END, 4-HT, and clomiphene 
simultaneously with Multiple Reaction Monitoring (MRM) mass 
spectrometry mode. The capillary pipe voltage was 3.5 kV with 
350 °C for desolvation temperature and 650 L/hour for the gas flow 
rate. The detection condition is shown in table 1. 
 
Table 1: Detection condition using MS/MS detector 
Compounds Parent ion (m/z) Daughter ion (m/z) Cone (V) Collision energy (V) 
TAM 372.2 72.27 50 27 
END 374.29 58.20 45 30 
4-HT 388.29 72.19 50 27 
Clomiphene 406.28 100.17 45 25 
 
Optimal conditions for the analysis can be obtained by optimizing the 
analysis and sample preparation method. Optimization of the mobile 
phase combination, composition, and flow rate was done to obtain a 
good separation. The mobile phase consisted of formic acid 0.1%-
formic acid 0.1% in acetonitrile (35:65) using an isocratic system with 
a flow rate of 0.25 ml/min. The analysis was performed in 4 min and 
peaks were separated in a short retention time, TAM (1.86 min), END 
(1.06 min), 4-HT (1.1 min), and clomiphene (1.4 min). 
Sample preparation is an important factor in bioanalysis because 
biological samples contain endogenous materials that can interfere 
with the analysis of compounds. Appropriate sample preparation is 
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necessary to minimize the disturbances in the analyses, so the 
accuracy of the analysis results can be obtained. Protein preparation 
was chosen because of its simplicity and efficiency [11, 12]. 
The optimum separation conditions for TAM, END, and 4-HT using 
the protein precipitation method with 1,000 μl methanol as the 
extraction solution and sonication was applied for 25 min. The 
samples were injected 10 μl into the LC-MS/MS system using a 0.1% 
formic acid-0.1% formic acid in acetonitrile (35:65) phase with 0.25 
ml/min resulted in retention time for TAM at 1.86 min, END at 1.11 
min, 4-HT at 1.15 min, and clomiphene at 1.41 min. 
The method proposed in the present study has several advantages 
over the methods reported in the literature for TAM, such as short 
analysis time (4 min per sample), simple sample preparation, and 
more convenient for the patient. Moreover, the method was used to 
measure the concentration of TAM and its metabolites (END and 4-
HT) for a clinical study of breast cancer patients. 
Validation assay 
Full validation assay has been conducted in the previous study and in 
the same laboratory. As shown in table 2, the intra and inter-assay 
precision and accuracy experiments performed on LLOQ and QC 
samples (QCL, QCM, and QCH) were fulfilled the requirement of EMA 
and FDA. Within run and between run imprecisions were in the 3.56 to 
8.67% and 4.2 to 10.82% ranges, respectively. Accuracy within run 
and between run was estimated at % bias-9.47 to 14.88% and-19.63 
(LLOQ) to 11.4%. LC with MS/MS methods should exclude any matrix 
effects. The effect of matrix was showed by analysis between the 
analyte area added after the blank extraction process compared to the 
area of standard solution in the solvent. As shown in table 2, this 
method showed acceptable matrix effect ranging from 85.78 to 
99.71% with variability (CV) under 10%. 
  
Table 2: Summary of full validation results 
Analyte QC Conc. 
(ng/ml) 
Precision (% CV) Accuracy (% bias) Matrix effect Internal standard-











%CV Mean %±SD) %CV 
TAM LLOQ 5.00 5.46 7.44 -7.33 -16.95     
QCL 25.00 4.71 4.20 -7.85 -9.90 85.78±2.32 2.71 0.89±0.02 2.41 
QCM 75.00 5.24 5.17 -6.15 10.25     
QCH 150.00 4.02 4.51 -6.15 -10.16 98.55±0.46 0.46 1.02±0.01 1.12 
END LLOQ 1.00 6.27 9.32 10.09 -19.63     
 QCL 5.00 8.25 5.93 -9.47 -12.63 93.71±2.74 2.92 0.97±0.03 3.54 
 QCM 15.00 3.56 5.40 -6.35 -12.29     
 QCH 30.00 5.20 4.11 -8.60 -8.60 92.93±8.35 8.98 0.96±0.08 8.82 
4-HT LLOQ 0.50 8.67 10.82 14.88 -18.11     
QCL 2.50 5.72 4.99 11.40 11.40 87.86±7.36 8.38 0.91±0.07 7.90 
QCM 7.50 7.66 7.17 10.25 -13.42     
QCH 15.00 4.65 5.21 -7.01 -12.22 99.61±7.71 7.74 1.03±0.08 7.94 
Clomiphene      96.91±0.89 0.92   
QC: Quality Control, LLOQ: Lower limit of Quantification, QCL: low level, QCM: medium level, QCH: high level, CV: variability, number of experiments (n): 3 
 
Table 3: Summary of partial validation results 
Analyte Linear regression QC Conc. (ng/ml) Precision Accuracy Recovery  
%CV % Bias %mean±SD %CV 
TAM y=0.0143+0.0115x 
r=0.9996 
LLOQ 5.00 4.90 -7.70   
 QCL 25.00 6.34 -12.90 71.27±4.34 6.09 
 QCM 75.00 5.42 -8.25 
 QCH 150.00 5.46 7.27 
END y=0.0003+0.0017x 
r=0.9977 
LLOQ 1.00 4.37 18.69   
 QCL 5.00 5.47 -10.88 81.15±4.33 5.34 
 QCM 15.00 2.18 -13.11 
 QCH 30.00 3.14 6.29 
4-HT y=0.0029+0.0034x 
r=0.9958 
LLOQ 0.50 14.44 17.60 81.87±7.80 9.52 
 QCL 2.50 10.25 11.01 
 QCM 7.50 7,36 -9.50 
 QCH 15.00 5,13 6.73 
Clomiphene      80.79±1.32 1.63 
QC: Quality Control, LLOQ: Lower limit of Quantification, QCL: low level, QCM: medium level, QCH: high level, CV: Coefficient Variation, number of 
experiments (n): 3 
 
The partial validation was performed in this study as shown in table 3. 
The linearity of each calibration curve was determined by plotting the 
peak area ratio (y) of the analyte to the internal standard versus the 
nominal concentration (x) of TAM, END, and 4-HT. The calibration 
curves were linear over the concentration range of 5.0-200.0 ng/ml for 
TAM; 1.0-40.0 ng/ml for END; and 0.5-20.0 ng/ml for 4-HT with a 
correlation coefficient of 0.99 for those three compounds.  
Accuracy and precision were calculated using within run and 
between run test at LLOQ, QCL, QCM, and QCH concentration levels. 
The accuracy (%bias value) TAM, END, and 4 HT were less than 
20%. The precision (%CV value) of TAM 4.90-6.34%; 2.18-4.37% for 
END; and 5.13-14.44% for 4-HT. Recovery was calculated using 
three replicates at three concentration levels: QCL, QCM, and QCH. 
The mean recovery (%recovery value) for TAM, END, and 4-HT was 
71.27±4.34 %; 81.15±4.33%; and 81.87±7.80with %CV value less 
than 15% for all compounds. The results showed that the method is 
reliable within the analytical range. 
This method was applied for the determination of DBS 
concentration of TAM, END and 4-HT in 29 patients with a daily dose 
of 20 mg TAM. Sampling was conducted in outpatient subject that 
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already reach steady state level of TAM. The results of the analysis 
on 29 samples showed that all samples contained TAM, END and 4-
HT. Our data showed a wide range of drug DBS concentrations 
among patients. 
  
Table 4: Result of analysis in breast cancer patients 
Patient Measured concentration (ng/ml) 
TAM END 4-HT 
SN 01 164.61 25.30 5.74 
SN 02 144.44 24.10 4.48 
SN 03 114.12 28.77 4.86 
SN 04 105.33 24.84 7.36 
SN 05 139.95 18.42 6.64 
SN 06 104.97 6.62 4.32 
SN 07 183.52 26.63 0.72 
SN 08 58.27 6.72 6.58 
SN 09 98.21 16.97 6.08 
SN 10 94.32 17.10 6.73 
SN 11 67.15 9.29 8.19 
SN 12 140.28 10.88 1.00 
SN 13 127.88 9.50 2.13 
SN 14 160.31 4.55 3.21 
SN 15 178.72 19.43 6.46 
SN 16 61.57 13.95 11.28 
SN 17 100.97 21.56 3.11 
SN 18 154.82 9.42 4.59 
SN 19 138.81 10.72 3.36 
SN 20 120.02 12.79 5.43 
SN 21 188.63 18.18 7.26 
SN 22 13.38 11.07 2.56 
SN 23 96.03 3.75 1.87 
SN 24 39.68 5.36 0.96 
SN 25 30.29 2.22 0.21 
SN 26 54.46 1.45 1.45 
SN 27 39.68 5.96 0.44 
SN 28 35.23 8.70 1.21 
SN 29 39.20 3.98 1.45 
The lowest TAM level was found in patient SN 25 of 30.29 ng/ml and the highest level of TAM which is 188.63 ng/ml was present inpatient SN 21. 
The mean value of TAM levels in DBS was 110.02 ng/ml with standard deviation of 47.68 and the coefficient of variation of 43.33%.  
 
 
Fig. 1: Graph of TAM, END and 4-HT analysis result in 29 patients (number of experiments (n: 29), n: 29, mean value of TAM: 110.02 
ng/ml±43.33%, END: 13.04 ng/ml±61.48%, 4-HT: 4.13 ng/ml±67.75% 
 
This variation between patients was also found in the results of END 
analysis. The lowest END levels were present in patient SN 26 of 
1.45 ng/ml and the highest levels of 28.77 ng/ml were present in 
patient SN 03. END levels in DBS had an average value of 13.04 
ng/ml with standard deviation of 8.02 and the variation coefficient 
of 61.48%. The results of 4-HT analysis also shown variation 
between patients. The lowest 4-HT level of 0.21 ng/ml was found in 
patient SN 25 and the highest level of 11.28 ng/ml was found in 
patient SN 16. 4-HT level in DBS had an average value of 4.13 ng/ml 
with standard deviation of 2.79 and the variation coefficient of 
67.75%. Based on the data obtained, it can be concluded that TAM, 
END, and 4-HT levels in the DBS between patients vary widely. The 
graph of TAM, END, 4-HT analysis in breast cancer patients is shown 
on fig. 1. The analytical result data is shown on table 4. 
Concentration range of END and 4-HT found in this study showed 
high variability. This shows that on the same dosage, different 
metabolism in every patient lead to different level of metabolites 
formation, thus affecting TAM efficacy. 
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The efficacy of TAM therapy in breast cancer patients is correlated 
to the END clinical threshold in blood. Based on the previous study, 
96% patient with END serum concentration above 5.9 ng/ml had a 
26% reduction of recurrences comparing with patients with END 
concentrations below the threshold [4]. This concentration is 
extrapolated to DBS, resulted in END threshold concentration of 3.3 
ng/ml in DBS. Based on the END threshold concentration, 2 patients 
have END concentration below the clinical threshold. The variation 
of concentrations may be attributed to the inter-individual 
pharmacokinetic variability, including polymorphisms of CYP2D6 
and CYP3A4 and drugs interaction [5, 13].  
CONCLUSION 
The developed method for determination TAM, END, and 4-HT using 
LC-MS/MS has a simple sample preparation and rapid analysis run 
time. This method met the 2011 European Medicines Agency (EMA) 
and 2013 Food and Drug Administration (FDA) bioanalytical 
guideline for validations. This method was successfully applied to 29 
breast cancer patients, including 2 patients with END level below the 
threshold concentration. 
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